Reuters：礼来旗下淋巴瘤药物Enzastaurin后期临床试验失败

5月10日，礼来表示将停止旗下淋巴瘤药物Enzastaurin的开发，因为该药物在一项后期临床试验中不能延迟淋巴瘤患者症状的恶化。这款药物当时正被用于检测对化疗治疗后复发的高风险淋巴瘤患者的疗效。

礼来在5月10日的一份声明中表示，停止该药物开发将会导致第二季度约3000万美元的费用损失，但该公司2013年的财务预算会保持不变。

礼来在过去的十年里还针对Enzastaurin进行了其它各种肿瘤的疗效检测，但均没有成功，这其中包括肺癌和乳腺癌。淋巴瘤是最后检测的重点。乐通公司已预测礼来会在今年将该药物作为一个淋巴瘤治疗药物提交上市申请，并且如果获得批准，其2016年的年销售额将会达到2亿美元。

如果Enzastaurin能够获批，对礼来的癌症药物项目将会有一个推动作用。礼来销售最好的第三大药物是用于肺癌治疗的力比泰，其年销售额达到25亿美元，但这个药物在美国的专利将在2016年到期，届时将面临仿制药的激烈竞争。

礼来在声明中还表示将会继续公司两个其它肿瘤试验药物的后期临床试验。礼来公司的股价在早盘交易中有微小的波动。

与淋巴瘤相关的拓展阅读：

• Clin Cancer Res：我国学者在旋覆花中发现新型抗淋巴瘤化合物
• JCI：原发性渗出性淋巴瘤或可协同治疗
• The Lancet：R-CHOP-21方案仍是新诊弥漫大B细胞淋巴瘤患者的标准一线方案
• Blood：开发出治疗淋巴瘤的新型疗法
• JCO：【评论】治疗滤泡性淋巴瘤的“一线之争” 更多信息请点击：有关淋巴瘤更多资讯

Eli Lilly lymphoma drug fails in late-stage trial
Eli Lilly and Co said it will end development of an experimental cancer drug after it failed in a late-stage trial to delay a worsening of symptoms in patients with lymphoma.
The drug, enzastaurin, was being tested in lymphoma patients who were at high risk of relapse following chemotherapy treatment. Lymphoma is a cancer of the lymphatic system.
The decision to stop the drug's development will result in a second-quarter charge of about $30 million, but the company's 2013 forecast remained unchanged, Lilly said in a statement on Friday.
Lilly over the past decade has also tested the pill against a variety of other types of tumors, without success, including lung cancer and breast cancer. Its main remaining focus has been on lymphoma.
Cowen and Co had expected Lilly to seek marketing approval for the medicine this year as a lymphoma treatment, and for it to generate annual sales by 2016 of about $200 million, if approved for the condition. That would have made it a fairly modest product for Lilly.
Approval would have given a boost to Lilly's cancer program. The company's third-biggest medicine is Alimta, a treatment for lung cancer that pulls in $2.5 billion a year, but it could face generic competition in the United States by 2016.
Lilly on Friday said it continues with late-stage trials of two other experimental cancer drugs.
Lilly shares were little changed in morning trading.